Skip to main content
. 2023 Mar 24;11(4):723. doi: 10.3390/vaccines11040723

Table 4.

Summary of saliva total Ig response.

High-Dose (n = 12) Low-Dose (n = 11) Placebo (n = 6) p-Value 1+ p-Value 2+ p-Value 3+ p-Value 4
Day 0 (pre-dose) 0.05 (0.03–0.10) 0.07 (0.04–0.11) 0.08 (0.03–0.13) 0.15 0.93 0.06 0.65
Day 3 0.26 (0.16–0.66) 0.18 (0.08–0.51) 0.32 (0.12–0.72) 0.83 0.99 0.84 0.87
Day 28 (pre-dose) 0.08 (0.03–0.24) 0.07 (0.04–0.17) 0.1 (0.03–0.13) 0.11 0.20 0.36 0.66
Day 31 0.24 (0.13–0.63) 0.21 (0.08–0.50) 0.21 (0.11–0.26) 0.046 0.06 0.99 0.59
Day 56 0.31 (0.09–0.61) 0.31 (0.07–0.48) 0.15 (0.06–0.53) 0.45 0.96 0.45 0.69

High-dose: DelNS1-nCoV-RBD LAIV (1 × 107.7 EID50/dose) in 0.2 mL. Low-dose: DelNS1-nCoV-RBD LAIV (1 × 107 EID50/dose) in 0.2 mL. Placebo: inert excipients/ dose in 0.2 mL. p-value 1: High-dose vs. Placebo. p-value 2: Low-dose vs. Placebo. p-value 3: High-dose vs. Low-dose. + Mann-Whitney U test. p-value 4: one-way ANOVA, comparison of three groups. Data were median (IQR).